JP2006507286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507286A5 JP2006507286A5 JP2004547181A JP2004547181A JP2006507286A5 JP 2006507286 A5 JP2006507286 A5 JP 2006507286A5 JP 2004547181 A JP2004547181 A JP 2004547181A JP 2004547181 A JP2004547181 A JP 2004547181A JP 2006507286 A5 JP2006507286 A5 JP 2006507286A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tnfα
- disease
- composition according
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 88
- 201000010099 disease Diseases 0.000 claims 35
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 35
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 31
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 31
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 26
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 26
- 208000024891 symptom Diseases 0.000 claims 24
- 239000000427 antigen Substances 0.000 claims 17
- 102000036639 antigens Human genes 0.000 claims 17
- 108091007433 antigens Proteins 0.000 claims 17
- 206010003246 arthritis Diseases 0.000 claims 17
- 230000000694 effects Effects 0.000 claims 13
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims 11
- 206010051728 Bone erosion Diseases 0.000 claims 10
- 206010061218 Inflammation Diseases 0.000 claims 10
- 210000000845 cartilage Anatomy 0.000 claims 10
- 230000003628 erosive effect Effects 0.000 claims 10
- 108020001507 fusion proteins Proteins 0.000 claims 10
- 102000037865 fusion proteins Human genes 0.000 claims 10
- 230000004054 inflammatory process Effects 0.000 claims 10
- 108010008165 Etanercept Proteins 0.000 claims 9
- 229960000403 etanercept Drugs 0.000 claims 9
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 9
- 230000001627 detrimental effect Effects 0.000 claims 8
- 230000002792 vascular Effects 0.000 claims 8
- 102000057041 human TNF Human genes 0.000 claims 6
- 229960000598 infliximab Drugs 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 229940116176 remicade Drugs 0.000 claims 4
- 210000002966 serum Anatomy 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000012659 Joint disease Diseases 0.000 claims 2
- 208000019693 Lung disease Diseases 0.000 claims 2
- 206010063837 Reperfusion injury Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 230000003412 degenerative effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000028774 intestinal disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 230000008961 swelling Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42126202P | 2002-10-24 | 2002-10-24 | |
| US60/421,262 | 2002-10-24 | ||
| PCT/US2003/033973 WO2004037205A2 (en) | 2002-10-24 | 2003-10-24 | LOW DOSE METHODS FOR TREATING DISORDERS IN WHICH TNFα ACTIVITY IS DETRIMENTAL |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011161229A Division JP5676386B2 (ja) | 2002-10-24 | 2011-07-22 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006507286A JP2006507286A (ja) | 2006-03-02 |
| JP2006507286A5 true JP2006507286A5 (https=) | 2007-03-08 |
| JP5594803B2 JP5594803B2 (ja) | 2014-09-24 |
Family
ID=32176690
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004547181A Expired - Fee Related JP5594803B2 (ja) | 2002-10-24 | 2003-10-24 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
| JP2011161229A Expired - Fee Related JP5676386B2 (ja) | 2002-10-24 | 2011-07-22 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
| JP2014181968A Pending JP2015028040A (ja) | 2002-10-24 | 2014-09-08 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011161229A Expired - Fee Related JP5676386B2 (ja) | 2002-10-24 | 2011-07-22 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
| JP2014181968A Pending JP2015028040A (ja) | 2002-10-24 | 2014-09-08 | ＴＮＦα活性が有害である疾患を治療するための低用量方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8846046B2 (https=) |
| EP (3) | EP1578439B1 (https=) |
| JP (3) | JP5594803B2 (https=) |
| KR (4) | KR20110000757A (https=) |
| CN (2) | CN1732015A (https=) |
| AR (2) | AR045710A1 (https=) |
| AT (1) | ATE517632T1 (https=) |
| AU (2) | AU2003301522B8 (https=) |
| BR (1) | BR0315597A (https=) |
| CA (1) | CA2497909A1 (https=) |
| DK (1) | DK1578439T3 (https=) |
| ES (1) | ES2370351T3 (https=) |
| MX (1) | MXPA05004344A (https=) |
| MY (1) | MY150740A (https=) |
| NZ (3) | NZ585493A (https=) |
| PE (1) | PE20040751A1 (https=) |
| PL (2) | PL398520A1 (https=) |
| PT (1) | PT1578439E (https=) |
| SA (1) | SA04240497A (https=) |
| SI (1) | SI1578439T1 (https=) |
| TW (3) | TWI423817B (https=) |
| UY (1) | UY28041A1 (https=) |
| WO (1) | WO2004037205A2 (https=) |
| ZA (1) | ZA200502983B (https=) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| MX336813B (es) * | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| CA2817619A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20040009172A1 (en) * | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20090280065A1 (en) * | 2006-04-10 | 2009-11-12 | Willian Mary K | Uses and Compositions for Treatment of Psoriasis |
| WO2004009776A2 (en) * | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | TREATMENT OF TNFα RELATED DISORDERS |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| WO2005023761A2 (en) * | 2003-09-11 | 2005-03-17 | Kemia, Inc. | Cytokine inhibitors |
| TW201705980A (zh) * | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
| WO2006041970A2 (en) * | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
| NZ595225A (en) | 2005-05-16 | 2013-05-31 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
| US20070041905A1 (en) * | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| CN103336129A (zh) * | 2005-11-01 | 2013-10-02 | 阿布维生物技术有限公司 | 使用生物标志物诊断强直性脊柱炎的方法和组合物 |
| WO2007058990A2 (en) * | 2005-11-14 | 2007-05-24 | Kemia, Inc. | Therapy using cytokine inhibitors |
| US8338397B2 (en) | 2006-01-19 | 2012-12-25 | The Regents Of The University Of Michigan | Composition and method of treating side effects from antibiotic treatment |
| US7951845B2 (en) | 2006-01-19 | 2011-05-31 | The Regents Of The University Of Michigan | Composition and method of treating hearing loss |
| US10238599B2 (en) | 2006-01-19 | 2019-03-26 | The Regents Of The University Of Michigan | Composition and method for treating congenital cytomegalovirus induced hearing loss |
| US9770433B2 (en) | 2006-01-19 | 2017-09-26 | The Regents Of The University Of Michigan | Composition and method for treating tinnitus |
| US9919008B2 (en) | 2006-01-19 | 2018-03-20 | The Regents Of The University Of Michigan | Method for treating age-related hearing loss (ARHL) |
| USRE46372E1 (en) | 2006-01-19 | 2017-04-25 | The Regents Of The Univerity Of Michigan | Method for treating hearing loss |
| US8927528B2 (en) | 2006-01-19 | 2015-01-06 | The Regents Of The University Of Michigan | Composition for treating hearing loss |
| US9889156B2 (en) | 2006-01-19 | 2018-02-13 | The Regents Of The University Of Michigan | Method for treating noise-induced hearing loss (NIHL) |
| CN102887955A (zh) | 2006-04-05 | 2013-01-23 | 艾博特生物技术有限公司 | 抗体纯化 |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
| US20080118496A1 (en) * | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US20090317399A1 (en) * | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| US20080131374A1 (en) * | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20080311043A1 (en) * | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| MX2008016335A (es) | 2006-06-30 | 2009-01-21 | Abbott Biotech Ltd | Dispositivo automatico de inyeccion. |
| ES2442258T3 (es) | 2006-10-27 | 2014-02-10 | Abbvie Biotechnology Ltd | Anticuerpos cristalinos anti-hTNF alfa |
| WO2008150491A2 (en) * | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
| JP2010528647A (ja) * | 2007-06-06 | 2010-08-26 | ドマンティス リミテッド | ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| JP2010533181A (ja) * | 2007-07-13 | 2010-10-21 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦα阻害剤の肺投与のための方法及び組成物 |
| WO2009020654A1 (en) | 2007-08-08 | 2009-02-12 | Abbott Laboratories | Compositions and methods for crystallizing antibodies |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US8883146B2 (en) | 2007-11-30 | 2014-11-11 | Abbvie Inc. | Protein formulations and methods of making same |
| US20090271164A1 (en) * | 2008-01-03 | 2009-10-29 | Peng Joanna Z | Predicting long-term efficacy of a compound in the treatment of psoriasis |
| CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
| PL2258361T3 (pl) * | 2008-03-27 | 2015-02-27 | Toyama Chemical Co Ltd | Zastosowanie pochodnej benzofenonu lub jej soli w kombinacji z inhibitorem TNFα i kompozycja farmaceutyczna zawierająca pochodną lub jej sól oraz inhibitor |
| WO2010127146A1 (en) | 2009-04-29 | 2010-11-04 | Abbott Biotechnology Ltd | Automatic injection device |
| US20100278822A1 (en) * | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| RU2582401C2 (ru) | 2009-12-15 | 2016-04-27 | Эббви Байотекнолоджи Лтд | Усовершенствованная пусковая кнопка для автоматического инъекционного устройства |
| EP2575884B1 (en) | 2010-06-03 | 2018-07-18 | AbbVie Biotechnology Ltd | Uses and compositions for treatment of hidradenitis suppurativa (hs) |
| UY33679A (es) | 2010-10-22 | 2012-03-30 | Esbatech | Anticuerpos estables y solubles |
| US8821865B2 (en) | 2010-11-11 | 2014-09-02 | Abbvie Biotechnology Ltd. | High concentration anti-TNFα antibody liquid formulations |
| RU2727040C2 (ru) | 2011-01-24 | 2020-07-17 | Эббви Байотекнолоджи Лтд. | Автоматические инъекционные устройства, имеющие наформованные поверхности захвата |
| US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| WO2012150325A1 (en) * | 2011-05-04 | 2012-11-08 | Cellmade Sas | Method for finding active pharmaceutical ingredients for the treatment of diseases associated with increased or decreased cytokine pathway activity |
| EP2520934A1 (en) * | 2011-05-04 | 2012-11-07 | CellMade SAS | Method for finding active pharmaceutical ingredients for the treatment of deseases associated with increased or decreased cytokine pathway activity |
| CA2850572A1 (en) * | 2011-10-20 | 2013-04-25 | Esbatech, A Novartis Company Llc | Stable multiple antigen-binding antibody |
| WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
| US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| HK1211981A1 (en) | 2012-09-02 | 2016-06-03 | Abbvie Inc. | Methods to control protein heterogeneity |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| HK1207960A1 (en) | 2013-03-12 | 2016-02-19 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| RU2676303C2 (ru) * | 2013-07-11 | 2018-12-27 | Новартис Аг | Использование антагониста vegf для лечения ретролентальной фиброплазии |
| US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| EP3057616B1 (en) | 2013-10-16 | 2020-03-11 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| WO2015198320A1 (en) | 2014-06-24 | 2015-12-30 | Insight Biopharmaceuticals Ltd. | Methods of purifying antibodies |
| WO2016023875A1 (en) * | 2014-08-14 | 2016-02-18 | F. Hoffmann-La Roche Ag | Combination therapy of antibodies activating human cd40 and antibodies against human pd-l1 |
| WO2016118707A1 (en) | 2015-01-21 | 2016-07-28 | Oncobiologics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| CA3255406A1 (en) | 2015-03-31 | 2025-07-03 | Sorriso Pharmaceuticals, Inc. | Tnf-alpha binding polypeptides |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| SG11201706840WA (en) | 2015-03-31 | 2017-09-28 | Vhsquared Ltd | Peptide construct having a protease-cleavable linker |
| EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
| CN104887687A (zh) * | 2015-05-27 | 2015-09-09 | 南京医科大学第一附属医院 | 美莎拉嗪在制备治疗坏疽性脓皮病的药物中的应用 |
| CN109563161A (zh) | 2016-02-03 | 2019-04-02 | 安口生物公司 | 用于提高抗体稳定性的缓冲制剂 |
| US20180126000A1 (en) | 2016-06-02 | 2018-05-10 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11154621B2 (en) * | 2017-06-27 | 2021-10-26 | Ohio State Innovation Foundation | Liponucleotide-based therapy for COPD |
| BR112020010694A2 (pt) | 2017-12-01 | 2020-11-10 | Abbvie Inc. | agonista de receptor de glicocorticoides e imunoconjugados do mesmo |
| CA3144567A1 (en) | 2019-06-21 | 2020-12-24 | Scott Crowe | Polypeptides |
| US12559552B2 (en) | 2019-06-21 | 2026-02-24 | Sorriso Pharmaceuticals, Inc. | IL-23 and TNF-alpha binding bi-specific heavy chain polypeptides |
| KR20220063148A (ko) | 2019-06-21 | 2022-05-17 | 소리소 파마슈티컬스 인크. | 조성물 |
Family Cites Families (132)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58501544A (ja) | 1981-09-08 | 1983-09-16 | ザ ロツクフエラ− ユニヴア−シテイ | エンドトキシン誘発メディエ−タ−（ショック検定）によるリポプロティンリパ−ゼの抑圧 |
| US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
| IL73883A (en) | 1984-12-20 | 1990-12-23 | Yeda Res & Dev | Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha |
| US4597966A (en) | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| EP0613006A1 (en) | 1985-08-16 | 1994-08-31 | The Rockefeller University | Antibodies to cachectin and immunoassays |
| US4870163A (en) | 1985-08-29 | 1989-09-26 | New York Blood Center, Inc. | Preparation of pure human tumor necrosis factor and hybridomas producing monoclonal antibodies to human tumor necrosis factor |
| EP0230574A3 (en) | 1986-01-31 | 1989-03-22 | Yale University | Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof |
| DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
| US5237054A (en) | 1987-02-20 | 1993-08-17 | Akzo Pharma | Stabilized aqueous composition containing antibodies |
| JPH03504499A (ja) | 1988-05-27 | 1991-10-03 | セントカー・インコーポレーテツド | 抗体試薬のための配合物 |
| NZ229922A (en) | 1988-07-18 | 1992-04-28 | Chiron Corp | Monoclonal antibodies specifically binding cachectin (tumor necrosis factor) and compositions |
| WO1990001191A2 (en) | 1988-07-27 | 1990-02-08 | Bmc Software, Inc. | Improved data transmission optimizer |
| US4897465A (en) | 1988-10-12 | 1990-01-30 | Abbott Laboratories | Enrichment and concentration of proteins by ultrafiltration |
| DE68914244T2 (de) | 1988-10-24 | 1994-10-27 | Otsuka Pharma Co Ltd | Monoklonaler Antikörper. |
| ATE147634T1 (de) | 1988-12-19 | 1997-02-15 | American Cyanamid Co | Produkte zur behandlung des endotoxin -schocks bei einem säugetier |
| JP3443119B2 (ja) | 1989-08-07 | 2003-09-02 | ペプテック リミテッド | 腫瘍壊死因子結合リガンド |
| US5998378A (en) | 1989-08-16 | 1999-12-07 | Chiron Corporation | Compositions for the inhibition of TNF hormone formation and uses thereof |
| GB8921123D0 (en) | 1989-09-19 | 1989-11-08 | Millar Ann B | Treatment of ards |
| JPH0791318B2 (ja) | 1989-09-21 | 1995-10-04 | 三井東圧化学株式会社 | 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤 |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5945098A (en) | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| DE4037604A1 (de) | 1990-04-25 | 1991-10-31 | Bayer Ag | Verwendung von anti-tnf-antikoerpern als arzneimittel bei der behandlung von ischaemien und deren folgen |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| JPH06500323A (ja) | 1990-08-27 | 1994-01-13 | ペプチド テクノロジィ リミテッド | ウイルス性感染の治療方法 |
| GB9109645D0 (en) | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
| GB2279077B (en) | 1990-12-21 | 1995-06-14 | Celltech Ltd | Therapeutic compositions comprising recombinant antibodies specific for the TNFalpha |
| US5994510A (en) | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
| GB9028123D0 (en) | 1990-12-28 | 1991-02-13 | Erba Carlo Spa | Monoclonal antibodies against human tumor necrosis factor alpha |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6277969B1 (en) * | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| EP1857553A1 (en) | 1991-03-18 | 2007-11-21 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
| ES2123515T3 (es) | 1991-03-29 | 1999-01-16 | Immunex Corp | Antagonistas de citoquinas a base de proteinas virales aisladas. |
| US6165467A (en) | 1991-07-20 | 2000-12-26 | Yoshihide Hagiwara | Stabilized human monoclonal antibody preparation |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| GB9122820D0 (en) | 1991-10-28 | 1991-12-11 | Wellcome Found | Stabilised antibodies |
| WO1993011793A1 (en) | 1991-12-17 | 1993-06-24 | Schering Corporation | Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock |
| JP3251587B2 (ja) | 1992-04-02 | 2002-01-28 | スミスクライン・ビーチャム・コーポレイション | 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物 |
| ES2121907T3 (es) | 1992-08-28 | 1998-12-16 | Bayer Ag | Uso de anticuerpos monoclonales anti-tnf para el tratamiento de meningitis bacterianas. |
| AU670125B2 (en) | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
| US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
| EP0671936A1 (en) | 1992-10-15 | 1995-09-20 | Dana-Farber Cancer Institute, Inc. | TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION |
| DE69427928T3 (de) | 1993-03-05 | 2012-05-10 | Bayer Healthcare Llc | Humane monoklonale anti-TNF alpha Antikörper |
| DE4307508A1 (de) | 1993-03-10 | 1994-09-15 | Knoll Ag | Verwendung von anti-TNF-Antikörpern als Arzneimittel bei der Behandlung von Herzinsuffizienz (Herzmuskelschwäche) |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| FR2708467B1 (fr) | 1993-07-30 | 1995-10-20 | Pasteur Merieux Serums Vacc | Préparations d'immunoglobulines stabilisées et procédé pour leur préparation. |
| EP0659766A1 (en) | 1993-11-23 | 1995-06-28 | Schering-Plough | Human monoclonal antibodies against human cytokines and methods of making and using such antibodies |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| NZ278607A (en) | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
| JPH09509835A (ja) | 1994-03-04 | 1997-10-07 | メルク エンド カンパニー インコーポレーテッド | アラニン走査型突然変異誘発によるｉｎ ｖｉｔｒｏ抗体アフィニティー成熟 |
| ZA955642B (en) | 1994-07-07 | 1997-05-06 | Ortho Pharma Corp | Lyophilized imaging agent formulation |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ES2434840T3 (es) | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| GB9705810D0 (en) | 1997-03-20 | 1997-05-07 | Common Services Agency | Intravenous immune globulin |
| AU6914998A (en) | 1997-04-07 | 1998-10-30 | Cangene Corporation | Intravenous immune globulin formulation containing a non-ionic surface active agent with improved pharmacokinetic properties |
| CA2635352C (en) | 1997-06-13 | 2012-09-11 | Genentech, Inc. | Stabilized antibody formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CN1149100C (zh) | 1997-10-23 | 2004-05-12 | 三菱制药株式会社 | 可室温贮存的免疫球蛋白静脉注射制剂 |
| AU2444899A (en) | 1998-01-22 | 1999-08-09 | Astrazeneca Ab | Pharmaceutical formulation comprising an antibody and a citrate buffer |
| US6419944B2 (en) | 1999-02-24 | 2002-07-16 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6423321B2 (en) * | 1999-02-24 | 2002-07-23 | Edward L. Tobinick | Cytokine antagonists for the treatment of sensorineural hearing loss |
| US6015557A (en) * | 1999-02-24 | 2000-01-18 | Tobinick; Edward L. | Tumor necrosis factor antagonists for the treatment of neurological disorders |
| US6537549B2 (en) * | 1999-02-24 | 2003-03-25 | Edward L. Tobinick | Cytokine antagonists for the treatment of localized disorders |
| US6177077B1 (en) | 1999-02-24 | 2001-01-23 | Edward L. Tobinick | TNT inhibitors for the treatment of neurological disorders |
| DE60003863T2 (de) | 1999-03-31 | 2004-04-22 | Pfizer Products Inc., Groton | Dioxocyclopentylhydroxamsäure |
| US20010021380A1 (en) | 1999-04-19 | 2001-09-13 | Pluenneke John D. | Soluble tumor necrosis factor receptor treatment of medical disorders |
| CA2371427A1 (en) | 1999-04-28 | 2000-11-09 | Yamanouchi Pharmaceutical Co., Ltd. | Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof |
| EP1173217B1 (en) | 1999-05-05 | 2005-10-19 | Merrion Research I Limited | Enhanced delivery of nucleic acid-based drugs |
| WO2001047554A1 (fr) | 1999-12-28 | 2001-07-05 | Chugai Seiyaku Kabushiki Kaisha | Compositions d'anticorps stables et preparations pour injection |
| US6585957B1 (en) | 2000-01-25 | 2003-07-01 | Aeropharm Technology Incorporated | Medicinal aerosol formulation |
| DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
| GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
| JP5490972B2 (ja) | 2000-08-04 | 2014-05-14 | 中外製薬株式会社 | タンパク質注射製剤 |
| UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
| JP5485489B2 (ja) | 2000-08-11 | 2014-05-07 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| SE0003045D0 (sv) | 2000-08-29 | 2000-08-29 | Probi Ab | New method |
| AU2002213441B2 (en) | 2000-10-12 | 2006-10-26 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| JP2004526674A (ja) | 2000-12-01 | 2004-09-02 | バテル・メモリアル・インスティテュート | 液体処方物中における生体分子の安定化のための方法 |
| KR20030074693A (ko) | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| KR20020066778A (ko) | 2001-02-13 | 2002-08-21 | 한국과학기술연구원 | 체내 난흡수 물질의 흡수촉진용 조성물과 제형 및 그의제조방법 |
| SE0101256D0 (sv) * | 2001-04-06 | 2001-04-06 | A & Science Invest Ab | Treatment of low back pain |
| US20030012786A1 (en) | 2001-05-25 | 2003-01-16 | Teoh Leah S. | Use of anti-TNF antibodies as drugs in treating septic disorders of anemic patients |
| JP5052736B2 (ja) | 2001-05-30 | 2012-10-17 | 中外製薬株式会社 | タンパク質製剤 |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| CA2817619A1 (en) * | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| JP4460892B2 (ja) | 2001-06-21 | 2010-05-12 | ジェネンテック インコーポレイテッド | 徐放性組成物 |
| MXPA04000747A (es) | 2001-07-25 | 2004-07-08 | Protein Desing Labs Inc | Formulacion farmaceutica liofilizada estable de anticuerpos igg. |
| TWI334439B (en) * | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| ATE414537T1 (de) | 2001-08-29 | 2008-12-15 | Chugai Pharmaceutical Co Ltd | Antikörper enthaltende stabilisierte zubereitungen |
| US6818613B2 (en) | 2001-11-07 | 2004-11-16 | Ortho-Mcneil Pharmaceutical, Inc. | Aqueous sustained-release formulations of proteins |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| GB0202633D0 (en) | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
| CN101721362B (zh) | 2002-02-14 | 2018-07-03 | 中外制药株式会社 | 包含抗体的溶液制剂 |
| US20030161828A1 (en) | 2002-02-19 | 2003-08-28 | Abbott Gmbh & Co. Kg | Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure |
| SI1478394T1 (sl) | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| US20040009172A1 (en) | 2002-04-26 | 2004-01-15 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
| CN1671741A (zh) | 2002-06-21 | 2005-09-21 | 拜奥根Idec公司 | 浓缩抗体的缓冲剂制剂及其使用方法 |
| CN1703233A (zh) | 2002-07-12 | 2005-11-30 | 米德列斯公司 | 防止蛋白氧化降解的方法和组合物 |
| WO2004009776A2 (en) | 2002-07-19 | 2004-01-29 | Abbott Biotechnology Ltd. | TREATMENT OF TNFα RELATED DISORDERS |
| US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| MY150740A (en) | 2002-10-24 | 2014-02-28 | Abbvie Biotechnology Ltd | Low dose methods for treating disorders in which tnf? activity is detrimental |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| TW201705980A (zh) | 2004-04-09 | 2017-02-16 | 艾伯維生物技術有限責任公司 | 用於治療ＴＮＦα相關失調症之多重可變劑量療法 |
| WO2006041970A2 (en) | 2004-10-08 | 2006-04-20 | Abbott Biotechnology Ltd. | Treatment of respiratory syncytial virus (rsv) infection |
| NZ595225A (en) | 2005-05-16 | 2013-05-31 | Abbott Biotech Ltd | Use of tnf inhibitor for treatment of erosive polyarthritis |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| CN103336129A (zh) | 2005-11-01 | 2013-10-02 | 阿布维生物技术有限公司 | 使用生物标志物诊断强直性脊柱炎的方法和组合物 |
| CN102887955A (zh) | 2006-04-05 | 2013-01-23 | 艾博特生物技术有限公司 | 抗体纯化 |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| WO2007120626A2 (en) | 2006-04-10 | 2007-10-25 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of ankylosing spondylitis |
| US20090317399A1 (en) | 2006-04-10 | 2009-12-24 | Pollack Paul F | Uses and compositions for treatment of CROHN'S disease |
| US9399061B2 (en) | 2006-04-10 | 2016-07-26 | Abbvie Biotechnology Ltd | Methods for determining efficacy of TNF-α inhibitors for treatment of rheumatoid arthritis |
| WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
| US20080131374A1 (en) | 2006-04-19 | 2008-06-05 | Medich John R | Uses and compositions for treatment of rheumatoid arthritis |
| US20100021451A1 (en) | 2006-06-08 | 2010-01-28 | Wong Robert L | Uses and compositions for treatment of ankylosing spondylitis |
| US20080311043A1 (en) | 2006-06-08 | 2008-12-18 | Hoffman Rebecca S | Uses and compositions for treatment of psoriatic arthritis |
| AU2007294731B2 (en) | 2006-09-13 | 2014-04-17 | Abbvie Inc. | Cell culture improvements |
| WO2008150491A2 (en) | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
| EP2152318A4 (en) | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
| WO2008154543A2 (en) | 2007-06-11 | 2008-12-18 | Abbott Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis |
| JP2010533181A (ja) | 2007-07-13 | 2010-10-21 | アボツト・バイオテクノロジー・リミテツド | ＴＮＦα阻害剤の肺投与のための方法及び組成物 |
| US8420081B2 (en) | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US20090271164A1 (en) | 2008-01-03 | 2009-10-29 | Peng Joanna Z | Predicting long-term efficacy of a compound in the treatment of psoriasis |
| TWI478937B (zh) | 2008-01-15 | 2015-04-01 | Abbvie Inc | 改良之哺乳動物表現載體及其用途 |
| CA2711984A1 (en) | 2008-01-15 | 2009-07-23 | Abbott Gmbh & Co. Kg | Powdered protein compositions and methods of making same |
-
2003
- 2003-10-23 MY MYPI20034055 patent/MY150740A/en unknown
- 2003-10-24 DK DK03809644.2T patent/DK1578439T3/da active
- 2003-10-24 KR KR1020107026478A patent/KR20110000757A/ko not_active Ceased
- 2003-10-24 AT AT03809644T patent/ATE517632T1/de active
- 2003-10-24 UY UY28041A patent/UY28041A1/es not_active Application Discontinuation
- 2003-10-24 WO PCT/US2003/033973 patent/WO2004037205A2/en not_active Ceased
- 2003-10-24 US US10/693,233 patent/US8846046B2/en not_active Expired - Lifetime
- 2003-10-24 PL PL398520A patent/PL398520A1/pl unknown
- 2003-10-24 PE PE2003001080A patent/PE20040751A1/es not_active Application Discontinuation
- 2003-10-24 CN CNA2003801074411A patent/CN1732015A/zh active Pending
- 2003-10-24 TW TW100105907A patent/TWI423817B/zh not_active IP Right Cessation
- 2003-10-24 SI SI200332033T patent/SI1578439T1/sl unknown
- 2003-10-24 JP JP2004547181A patent/JP5594803B2/ja not_active Expired - Fee Related
- 2003-10-24 AR ARP030103906A patent/AR045710A1/es unknown
- 2003-10-24 KR KR1020057007014A patent/KR20050083805A/ko not_active Ceased
- 2003-10-24 PL PL376705A patent/PL213215B1/pl unknown
- 2003-10-24 EP EP03809644A patent/EP1578439B1/en not_active Expired - Lifetime
- 2003-10-24 EP EP10182448A patent/EP2332565A1/en not_active Withdrawn
- 2003-10-24 EP EP10181959A patent/EP2295071A1/en not_active Withdrawn
- 2003-10-24 BR BR0315597-8A patent/BR0315597A/pt not_active IP Right Cessation
- 2003-10-24 MX MXPA05004344A patent/MXPA05004344A/es active IP Right Grant
- 2003-10-24 NZ NZ585493A patent/NZ585493A/en not_active IP Right Cessation
- 2003-10-24 AU AU2003301522A patent/AU2003301522B8/en not_active Ceased
- 2003-10-24 KR KR1020147025727A patent/KR20140117697A/ko not_active Withdrawn
- 2003-10-24 PT PT03809644T patent/PT1578439E/pt unknown
- 2003-10-24 ES ES03809644T patent/ES2370351T3/es not_active Expired - Lifetime
- 2003-10-24 CN CN201310140246.4A patent/CN103623408A/zh active Pending
- 2003-10-24 TW TW092129599A patent/TWI361696B/zh not_active IP Right Cessation
- 2003-10-24 NZ NZ539332A patent/NZ539332A/en not_active IP Right Cessation
- 2003-10-24 CA CA002497909A patent/CA2497909A1/en not_active Abandoned
- 2003-10-24 KR KR1020117030418A patent/KR20120013443A/ko not_active Abandoned
- 2003-10-24 TW TW102126999A patent/TW201345552A/zh unknown
- 2003-10-24 NZ NZ596945A patent/NZ596945A/xx not_active IP Right Cessation
-
2004
- 2004-02-11 SA SA04240497A patent/SA04240497A/ar unknown
-
2005
- 2005-04-13 ZA ZA200502983A patent/ZA200502983B/en unknown
-
2010
- 2010-07-14 AR ARP100102561A patent/AR077573A2/es unknown
- 2010-07-29 AU AU2010206042A patent/AU2010206042B2/en not_active Ceased
-
2011
- 2011-07-22 JP JP2011161229A patent/JP5676386B2/ja not_active Expired - Fee Related
-
2014
- 2014-02-19 US US14/183,845 patent/US20140200332A1/en not_active Abandoned
- 2014-09-08 JP JP2014181968A patent/JP2015028040A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507286A5 (https=) | ||
| Aringer et al. | Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention | |
| Aringer et al. | The role of tumor necrosis factor-alpha in systemic lupus erythematosus | |
| US6235281B1 (en) | Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 | |
| US20120225069A1 (en) | Use of a compound for reducing the biological effectiveness of il-6 | |
| JP2012021001A5 (https=) | ||
| JPH06506446A (ja) | 腫瘍壊死因子媒介疾患の治療方法 | |
| US20070036788A1 (en) | Use of a compound for reducing the biological effectiveness of il-6 | |
| JPS62201822A (ja) | 自己免疫性疾病の予防・治療剤 | |
| JP2005523946A5 (https=) | ||
| SA04240497A (ar) | طرق لمعالجة اضطرابات حيث تكون فعالية عامل النخر الورمي ألفا ضارة وذلك بإعطاء جرعات علاجية منخفضة | |
| EP1975180A1 (en) | Treatment of autoimmune diseases with antibody anti gamma interferon | |
| Odobasic et al. | Distinct in vivo roles of CD80 and CD86 in the effector T‐cell responses inducing antigen‐induced arthritis | |
| EP0936923A1 (en) | SUPPRESSION OF TNF $g(a) AND IL-12 IN THERAPY | |
| D'Haens | Anti-TNF therapy for Crohn's disease | |
| JP2009506095A (ja) | 慢性全腸炎の治療のための、抗−ＴＮＦα産生乳酸菌 | |
| Granel et al. | Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome | |
| JP5646506B2 (ja) | 腸の炎症性疾患及び１型糖尿病を治療するためのａｐｌ型ペプチドの使用 | |
| Hodson | Vasculitis and arthropathy in cystic fibrosis | |
| JP6475847B2 (ja) | 過免疫反応によって誘発される炎症性疾患治療用組成物 | |
| Saji et al. | Infliximab for Kawasaki syndrome | |
| CN107661501A (zh) | 一种治疗强直性脊柱炎的药物组合物、药物靶点及其应用 | |
| CN114699410A (zh) | 千金藤素用于制备治疗类风湿关节炎药物的用途 | |
| Chandra et al. | Adalimumab-induced anti-neutrophilic cytoplasmic antibody vasculitis: A rare complication of an increasingly common treatment | |
| CN118021853A (zh) | 植物乳杆菌bx62在类风湿关节炎中的制药用途 |